207 related articles for article (PubMed ID: 31040713)
1. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AKC; Tang NLS; Lee KF; Lai PBS; Yu SCH; Yeo W
Cancer Manag Res; 2019; 11():2719-2727. PubMed ID: 31040713
[TBL] [Abstract][Full Text] [Related]
2. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
4. The association of liver function and quality of life of patients with liver cancer.
Li L; Mo F; Hui EP; Chan SL; Koh J; Tang NLS; Yu SCH; Yeo W
BMC Gastroenterol; 2019 May; 19(1):66. PubMed ID: 31046687
[TBL] [Abstract][Full Text] [Related]
5. Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma.
Serrano D; Podger L; Barnes G; Song J; Tang B
Qual Life Res; 2022 Mar; 31(3):937-950. PubMed ID: 34518988
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18).
Mikoshiba N; Tateishi R; Tanaka M; Sakai T; Blazeby JM; Kokudo N; Koike K; Kazuma K
Health Qual Life Outcomes; 2012 May; 10():58. PubMed ID: 22651810
[TBL] [Abstract][Full Text] [Related]
7. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18.
Chie WC; Blazeby JM; Hsiao CF; Chiu HC; Poon RT; Mikoshiba N; Al-Kadhimi G; Heaton N; Calara J; Collins P; Caddick K; Costantini A; Vilgrain V; Trinquart L; Chiang C;
Hepatology; 2012 Apr; 55(4):1122-9. PubMed ID: 22105642
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
9. Value of quality of life analysis in liver cancer: A clinician's perspective.
Li L; Yeo W
World J Hepatol; 2017 Jul; 9(20):867-883. PubMed ID: 28804570
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
11. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma.
Chie WC; Blazeby JM; Hsiao CF; Chiu HC; Poon RT; Mikoshiba N; Al-Kadhim G; Heaton N; Calara J; Collins P; Caddick K; Costantini A; Vilgrain V;
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e304-e311. PubMed ID: 27038366
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
13. Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life.
Mikoshiba N; Miyashita M; Sakai T; Tateishi R; Koike K
Psychooncology; 2013 Oct; 22(10):2347-53. PubMed ID: 23686523
[TBL] [Abstract][Full Text] [Related]
14. Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
Gough N; Koffman J; Ross JR; Riley J; Judson I
PLoS One; 2019; 14(9):e0210731. PubMed ID: 31557183
[TBL] [Abstract][Full Text] [Related]
15. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization.
Hinrichs JB; Hasdemir DB; Nordlohne M; Schweitzer N; Wacker F; Vogel A; Kirstein MM; Marquardt S; Rodt T
Cardiovasc Intervent Radiol; 2017 Oct; 40(10):1559-1566. PubMed ID: 28488104
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker MS; Potthoff SK; Lena A; Porthun J; Hadzibegovic S; Evertz R; Denecke C; Fröhlich AK; Sonntag F; Regitz-Zagrosek V; Rosen SD; Lyon AR; Lüscher TF; Spertus JA; Anker SD; Karakas M; Bullinger L; Keller U; Landmesser U; Butler J; von Haehling S
Eur J Heart Fail; 2023 Sep; 25(9):1635-1647. PubMed ID: 37369985
[TBL] [Abstract][Full Text] [Related]
17. The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study.
Li Q; Lin Y; Qiu Y; Gao B; Xu Y
Eur J Oncol Nurs; 2014 Aug; 18(4):425-35. PubMed ID: 24721179
[TBL] [Abstract][Full Text] [Related]
18. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18.
Blazeby JM; Currie E; Zee BC; Chie WC; Poon RT; Garden OJ;
Eur J Cancer; 2004 Nov; 40(16):2439-44. PubMed ID: 15519517
[TBL] [Abstract][Full Text] [Related]
19. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
20. Validation of EORTC QLQ-C30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer patients in Singapore.
Tan ML; Idris DB; Teo LW; Loh SY; Seow GC; Chia YY; Tin AS
Asia Pac J Oncol Nurs; 2014; 1(1):22-32. PubMed ID: 27981079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
